Aging, obesity and skyrocketing diabetes are projected to triple the medical costs for cardiovascular disease by 2030.

- 1 in 4 people over 65 has diabetes and 2 out of 4 are pre-diabetic.
- Diabetes is the leading cause of amputation and kidney failure.
- Life-saving dialysis is frequently interrupted by vascular access blockages.
- Over 10 million Americans have peripheral artery disease. PAD can block arteries and prevent blood flow throughout the leg.

The most severe form of PAD is critical limb ischemia, affecting more than 1 million Americans, of whom 30% die within 5 years. Many of our Wylie Scholars are working on projects to improve blood flow and prevent the need for amputation. These include Dr. Katherine Gallagher at the University of Michigan (2012) whose research into the effect of diabetes on stem cells may lead to new treatments for wounds that won’t heal. Drs. Richard Powell at Dartmouth (1999) and Edith Tzeng at the University of Pittsburgh (2001) recently participated in a clinical trial using patients’ own stem cells to repair damaged blood vessels in the leg.

**Building The Vascular Cures Research Network and Biobank**

Vascular Cures Research Network (VCRN) is well underway as we work to solve the mystery of why 30-50% of leg bypass, angioplasty and stent procedures fail due to over-healing and re-blockage. Collaborators at the University of Washington and VA Puget Sound (Seattle) have made major contributions to VCRN. In our first pilot study, Drs. Michael Conte (UCSF) and Alec Clowes (UW) identified a gene that improves healing after leg bypass surgery by 250%. Dr. Clowes is evaluating the role of this gene in dialysis access failure and carotid artery disease. Your support has been and remains crucial as we expand the program.

**10 Centers: $8M Expansion Campaign**

2011

- VCRN is launched
- The Scientific Advisory Board (SAB) is created
- Pilot project completed by University of Washington and UCSF
- **First biomarker** to improve healing after bypass surgery is identified: ‘P27’

2012

- VCRN infrastructure is completed:
  - Biorepositories to store and analyze patient samples
  - Database to manage patient and research information
  - Patient care protocols, informed consent procedures
- Patient #1 at UCSF
- 3 new members in SAB
- Centers: UCSF

2013

- Expansion campaign launched
- 8 patients enrolled as of April 2013
- 85 patients by the end of the year
- Add members to SAB

2014 - 2016

- 10 centers by the end of 2014
- 2000 patients enrolled by mid-2016
- 3 corporate partnerships
- 2 new biomarkers identified

Centers:
- UCSF and SF VA
- VA Puget Sound (Seattle)
- Dartmouth-Hitchcock
- 2 TBD
Joining Vascular Cures: Experts in Developing New Therapies

Russell Cox has joined our Board of Directors. He is Chief Commercial Officer at Jazz Pharmaceuticals, a specialty biopharmaceutical company. He has over 25 years of experience in biotech drug development, including work at Genentech on tPA, a leading treatment to minimize the effects of stroke.

Two members have been added to our Scientific Advisory Board. Dr. Charles Serhan is a leading researcher of novel ways to reduce vascular inflammation and restore blood flow to organs and tissues (reperfusion). He is Director of the Center for Experimental Therapeutics and Reperfusion Injury at Brigham and Women's Hospital in Boston, and a Professor at Harvard Medical School.

Dr. Campbell Rogers is an interventional cardiologist and Chief Medical Officer at HeartFlow, a cardiovascular diagnostics company. He was previously Chief Scientific Officer at Cordis Corporation, a Johnson & Johnson company that has pioneered less invasive treatments for vascular disease.

Making a Difference in Patient Lives

Margaret (Peggy) Stiegele, a long time supporter of Vascular Cures, passed away recently at the age of 90. Peggy was previously a patient of Dr. Ron Stoney, our co-founder, and her gratitude for her care resulted in significant gifts to support Vascular Cures programs. In 1998 her compassionate spirit led her to make an inspirational $1 million grant to Vascular Cures from the Gertrude Nielsen Trust ($50,000 per year for 20 years).

She had a special interest in the Wylie Scholar program and supporting a new generation of vascular surgeon-scientists. In addition, we are very grateful to Peggy for a generous bequest and her legacy will live on in our important work to advance treatments for vascular disease. Peggy will truly be missed, and is an example of "a life well lived". If you are interested in learning more about estate planning or including us in your will, please contact Wendy Hitchcock at wendy@vascularcures.org

Please Help Us Grow!

Our goal is to raise $8 million over the next three years to continue the Wylie Scholar program and expand the Vascular Cures Research Network and Biobank. 2013 is our crucial expansion year and your multi-year pledges would be gratefully appreciated. You can donate online at www.vascularcures.org or by using the enclosed envelope.

Your investment will help millions of patients, and every dollar is multiplied—we enable $5 in funding for every $1 received!

Save the Date

Annual Gala to Support Vascular Research

Saturday, September 28, 2013

Menlo Circus Club

Atherton, CA

Let us know if you’d like to receive communications electronically by emailing us at info@vascularcures.org.